Portfolio Strategies (Washington)’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Portfolio Strategies (Washington)’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$1.87M	Buy	+22,058	New	+$1.85M	3.74%	8

Other funds holding XBI

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Portfolio Strategies (Washington)'s XBI Position: Q4 2017 in Review

Portfolio Strategies (Washington) opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q4 2017: 22,058 shares worth $1.87M. The stake represents 3.74% of the portfolio and ranks #8 among its holdings.

397 funds tracked by Wall St. Rank hold XBI as of Q4 2017.

Portfolio Strategies (Washington) held 22,058 shares of State Street SPDR S&P Biotech ETF worth $1.87M as of Q4 2017.
State Street SPDR S&P Biotech ETF was a new Portfolio Strategies (Washington) position in Q4 2017.
State Street SPDR S&P Biotech ETF made up 3.74% of Portfolio Strategies (Washington)'s portfolio in Q4 2017, its #8 holding.
397 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2017.

Based on Portfolio Strategies (Washington)'s 13F filing for Q4 2017, filed 13 Feb 2018.